Maze Therapeutics
NASDAQ: MAZEFounded 2019 · Incorporated in Delaware · 4 known investors
Maze Therapeutics develops precision medicines for kidney disease and other conditions with large unmet medical needs, using a genetic variant-based approach through its Compass platform. The company designs therapeutics that mimic protective genetic variants to halt disease progression.
Investors · 4
In the news
- Maze Therapeutics (MAZE) Stock Looks Fully Priced After A 59% Gain## - Simply Wall St Newssimplywall.st · 2026
- What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?finance.yahoo.com · 2026
- Maze Therapeutics (MAZE) Rebounds This Week, Is The Upside Already Priced In?sahmcapital.com · 2026
- What's Behind ARCH Venture Management's Reduced Stake in Maze Therapeuticskavout.com · 2026
- Maze Therapeutics Raises Fresh Capital As R&D Plans And Valuation Diverge - Simply Wall St Newssimplywall.st · 2026
- $150M Oversubscribed Funding: Biotech Maze Therapeutics Attracts Major Healthcare Investors at Premium Pricestocktitan.net · 2025